Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medicover ABLTS:0RPS -0.11%91 Debt-to-EBITDA is 3.47 as of Jun. 2026, which is 8% below its 10-year median of 3.77. GuruFocus rates LTS:0RPS with a GF Score™ of 91/100 and a GF Value™ of kr230.34 (Fairly Valued). The stock has 5 warning signs investors should review. Among 476 Healthcare Providers & Services companies, Medicover AB ranks worse than 67.44% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Medicover AB's Debt-to-EBITDA or its related term are showing as below:
LTS:0RPS'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 2.42 Med: 3.77 Max: 5.24
Current: 3.72
During the past 12 years, the highest Debt-to-EBITDA Ratio of Medicover AB was 5.24. The lowest was 2.42. And the median was 3.77.
LTS:0RPS's Debt-to-EBITDA is ranked worse than 67.44% of 476
companies
in the Healthcare Providers & Services industry
Industry Median: 2.195
vs LTS:0RPS: 3.72
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Medicover AB Debt-to-EBITDA Related Terms
Medicover AB Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Medicover AB's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0RPS vs HCA, THC, DVA: Debt-to-EBITDA Comparison
For the Medical Care Facilities subindustry, Medicover AB's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medicover AB Debt-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Medicover AB's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Medicover AB's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Medicover AB (LTS:0RPS) has a Debt-to-EBITDA of 3.47 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Medicover AB. This is near median its historical median of 3.77. Over the past decade, Medicover AB's Debt-to-EBITDA has ranged from 2.42 to 5.24. According to the industry distribution chart, Medicover AB ranks #321 out of 476 companies in the Healthcare Providers & Services industry, placing it in the top 67.4%.
Is Medicover AB's Debt-to-EBITDA too high?
Medicover AB's current Debt-to-EBITDA of 3.47 is near median its 10-year median of 3.77. Over the past 10 years, this metric has ranged from a low of 2.42 to a high of 5.24. The Healthcare Providers & Services industry median Debt-to-EBITDA is 2.20. Medicover AB's value of 3.47 is 58.1% above this industry median. Based on the distribution chart, Medicover AB ranks #321 out of 476 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Medicover AB has a GF Score™ of 91/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Medicover AB's Debt-to-EBITDA compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Medicover AB ranks #321 out of 476 companies for Debt-to-EBITDA. This places Medicover AB in the lower half of its industry. The industry median Debt-to-EBITDA is 2.20. Medicover AB's value of 3.47 is 58.1% above this benchmark. Historically, Medicover AB's own Debt-to-EBITDA has ranged from 2.42 to 5.24 over the past decade. While the company's 10-year median is 3.77 vs. the industry median of 2.20, Medicover AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.20, based on 476 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medicover AB's current Debt-to-EBITDA of 3.47 is 58.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Medicover AB. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medicover AB's current Debt-to-EBITDA is 3.47, which is near median its own 10-year median of 3.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medicover AB stock overvalued right now?
Based on GuruFocus' analysis, Medicover AB (LTS:0RPS) is currently considered Fairly Valued. The stock's GF Value™ is kr230.34, compared to a current price of kr223.50 — trading 3% below its estimated fair value. The current Debt-to-EBITDA is 3.47, which is near median its 10-year median of 3.77 and 58.1% above the Healthcare Providers & Services industry median of 2.20. Medicover AB's overall GF Score™ is 91/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Medicover AB (LTS:0RPS), the current Debt-to-EBITDA is 3.47 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medicover AB (LTS:0RPS) Overvalued in 2026?
Based on GuruFocus' analysis, Medicover AB stock appears to be undervalued.
The current stock price of kr223.50 is trading 3% below its estimated GF Value™ of kr230.34.
GuruFocus considers Medicover AB to be Fairly Valued.
Key valuation signals for LTS:0RPS:
Debt-to-EBITDA: 3.47 (near median its 10-year median of 3.77)
GF Value™: kr230.34 vs. price of kr223.50 (3% below fair value)
Industry Position: 58.1% above the Healthcare Providers & Services median (#321 of 476)
No single metric tells the full story. See the LTS:0RPS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medicover AB is an international healthcare and diagnostic services provider. It offers a broad spectrum of healthcare services via an extensive network of ambulatory clinics, hospitals, specialty-care facilities, and laboratories. Medicover offers its services through two reportable segments: Healthcare Services, which generates the maximum revenue, and Diagnostic Services. Diagnostic Services offer a broad range of laboratory testing in all clinical pathology areas, and Healthcare Services offer medical care and related services by operating on an Integrated Healthcare and Fee-For-Service model across different countries. Geographically, the company derives maximum revenue from Germany, and the rest from Poland, India, Ukraine, Romania, and other countries.
91GF Score
Get the complete analysis for LTS:0RPS
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0RPS has been successfully added to your 
